#### 1 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible 2 serious bacterial infections in infants: a modeling analysis in two settings

3

8

- 4 Authors: Joshua M Chevalier\* (a), Megan A Hansen\* (a), Kyra H Grantz (a, b), Birgitta
- 5 Gleeson (b), Benjamin Blumel (b), Veronicah Chuchu (b), Shaukat Khan (b), Ntombi Sigwebela
- (c), Gwendoline Chimhini (d), Felicity Fitzgerald (e), Cecilia Ferreyra<sup>†</sup> (b), Brooke E Nichols<sup>†</sup> 6
- 7 (a, b, f)

#### 9 Affiliations:

- 10 a. Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands 11
- b. FIND, Geneva, Switzerland 12
- 13 c. FIND, Cape Town, South Africa
- 14 d. Department of Child Adolescent and Women's Health, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe 15
- e. Department of Infectious Diseases, Imperial College London, London, United Kingdom 16
- f. Department of Global Health, Boston University School of Public Health, Boston, MA, 17 USA 18
- 19
- 20 Correspondence: BE Nichols - brooken@bu.edu
- 21
- 22 \*Equal contribution
- 23 <sup>†</sup>Equal contribution

# 24 Abstract:

25

## 26 Introduction

- 27 Sepsis accounts for up to 50% of neonatal deaths in resource-limited countries. Accurate and
- 28 timely diagnosis could improve clinical outcomes, reduce inappropriate antibiotic use, and
- 29 provide healthcare cost savings. We aimed to identify the minimum technical specifications and
- 30 cost required of a point-of-care test (POCT) for neonatal sepsis to be clinically useful in hospital
- 31 and community levels in low-resource settings.
- 32

# 33 Methods

- 34 We modeled the diagnosis and treatment of two cohorts: hospitalized neonates and infants
- 35 presenting to primary health care facilities with suspected sepsis. We compared health outcomes,
- 36 including mortality, length of hospital stays, and acquisition of healthcare-associated infections
- 37 (HAIs), under a POCT compared to empiric treatment and blood culture across varying test
- 38 performance, prevalence of bacterial infection and discharge eligibility. A threshold health
- 39 economic analysis was performed to determine the allowable POCT price to remain cost neutral
- 40 to the healthcare system.
- 41

# 42 **Results**

- 43 A POCT could lead to a net reduction in neonatal deaths at both the hospital level (up to 19% of
- 44 deaths averted compared to baseline) and community level (up to 76% deaths averted) through
- 45 faster initiation of appropriate therapy and reducing unnecessary hospitalizations and HAIs.
- 46 Healthcare costs could be reduced substantially with implementation of a POCT (17%–43% of
- 47 baseline costs saved in hospital and 48%–81% saved in primary healthcare settings across the
- 48 range of analyzed scenarios), suggesting a POCT costing up to \$21 in hospitals and \$3 in
- 49 community settings could be cost neutral.
- 50

# 51 *Conclusions*

- 52 A POCT for neonatal sepsis, even with imperfect accuracy, could substantially improve clinical
- 53 outcomes by improving time to diagnosis, while also supporting antibiotic de-escalation and
- 54 stewardship and lowering healthcare costs. However, high clinical sensitivity is required to avoid
- 55 causing deaths through missed diagnoses due to false negative results and delayed antibiotic
- 56 initiation.

# 57 Key Questions

58

## 59 What is already known on this topic?

- 60 It is known that neonatal sepsis and possible serious bacterial infections in infants are a serious
- 61 cause of mortality; however, diagnosis to provide proper treatment and care remains difficult.
- 62

# 63 What does this study add?

- 64 This study generates evidence on what the technical specifications and costs are required of a
- 65 novel point-of-care test through mathematical modeling.
- 66

# 67 How might this study affect research, practice, or policy?

- 68 These results can be used as criteria to guide the development of a novel point-of-care test for
- 69 neonatal sepsis and bacterial infection in infants.

#### Introduction 71

72

73 Sepsis is a significant cause of neonatal (0-28 days-old) mortality worldwide, accounting for

7.3% of all neonatal deaths(1). Low- and middle-income countries with limited resources bear a 74

75 disproportionate burden of neonatal sepsis, with infections presenting both in hospital and

76 primary health care (PHC) settings (2).

77

Diagnosing neonatal sepsis is difficult due to nonspecific symptoms (fever, vomiting, irritability, 78

- 79 etc.) and a lack of readily available, easy-to-use diagnostic tests. Diagnostic testing is particularly
- 80 challenging in resource-limited settings, as many lack laboratory infrastructure to routinely
- 81 perform blood culture as a first step in the etiologic diagnosis and treatment of sepsis (3,4).
- Microbiology services, including culture and antibiotic susceptibility testing, are typically only 82
- 83 available at higher-level facilities (5). Even where microbiology services are available, the
- challenge of sufficient blood-draw volume, long turnaround times, and poor quality pathogen 84
- 85 identification and antibiotic susceptibility testing can limit the clinical utility of test results (6).
- 86

87 Without timely and adequate diagnosis, hospitalized neonates or infants suspected of sepsis are

- 88 treated empirically with broad-spectrum antibiotics, potentially leading to overuse of antibiotics
- 89 and unnecessary hospitalization of those without bacterial infections. Antibiotic overuse in this
- 90 age group can lead to morbidity and mortality, especially in low birthweight or preterm
- 91 newborns, while also contributing to the growing concern of antimicrobial resistance (AMR)
- 92 (7,8). Continued hospitalization of otherwise healthy neonates puts them at risk of healthcare-
- 93 associated infections (HAIs) – a major cause of sepsis (9).
- 94
- 95 At the community level, there are often no diagnostic tools available for infants with possible 96 serious bacterial infections (pSBI) (10). Current standard practice for infants with critical illness 97 or clinical severe infection classifications of pSBI at a PHC facility is to provide a single dose of 98 antibiotics and referral to the nearest hospital with greater access to the necessary tools for care
- 99
- (4,11). However, if referral is not feasible due to distance, cost, and/or time required, antibiotic
- 100 injections may be provided at the PHC level (12). This broad-scale treatment and referral to
- 101 higher-level care, even for infants without true bacterial infections, results in unnecessary
- 102 antibiotic use and hospitalization.
- 103

104 New diagnostic tools to identify sepsis and pSBI in neonates and infants could greatly improve 105 clinical management, guide referral decisions, and reduce misdiagnosis or unnecessary treatment 106 (4,13). A diagnostic tool, whether in the form of an algorithm or a point-of-care test (POCT) for

- 107 neonatal/infant sepsis must meet certain technical specifications (sensitivity, specificity) and a
- 108 realistic price to be clinically useful and feasible to implement (3,4). To better understand these
- 109 minimum diagnostic tool criteria and their impact on health-outcomes, we modeled the clinical
- 110 cascades of neonates born in a hospital and infants presenting at PHC facilities suspected of

- 111 sepsis using the current standard-of-care and using a POCT with same day results, similar to a
- 112 rapid diagnostic test. We then conducted a threshold health economic analysis to determine the
- 113 prices at which implementation of a POCT would be cost neutral to the health system. This
- 114 analysis provides important evidence to guide the development, implementation, and evaluation
- 115 of novel diagnostic tools for neonatal sepsis.
- 116

#### 117 **Methods**

118

119 To evaluate the potential impact of a true POCT for neonatal sepsis, we modeled diagnosis and

- 120 clinical care of two cohorts with pSBI: 1) hospital-born neonates 0–28 days of age and 2)
- 121 0–59 days of age presenting for care at the PHC level. Both models are parameterized using data
- 122 from India and Uganda, where the best data are available, and lower-income multi-country
- 123 implementation studies (**Table 1**). Both models were built using R version 4.3.1, and analyses
- 124 were conducted using R and Microsoft Excel version 16.81. Since modeling methods were used,
- 125 patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.
- 126
- 127

#### 128 Cohort 1: Hospitalized neonates

129

130 The modeled population consisted of 1,000 hospital-born neonates suspected of sepsis due to risk 131 factors (early gestational age, low birthweight) or clinical signs indicative of sepsis (fever, 132 difficulty breathing, inconsistent heart rate). We varied the prevalence of true bacterial sepsis 133 (i.e., prevalence of culture-positive sepsis). AMR infections, which accounted for 50% of all 134 sepsis cases, were associated with a nearly doubled case fatality rate (CFR) compared to

135 antibiotic susceptible infections. Relevant population parameters are summarized in **Table 1**.

- 136 Figure 1A displays the testing and clinical care cascade of the modeled population.
- 137
- 138 Under the baseline standard-of-care, all neonates with suspected sepsis immediately received
- 139 empiric antibiotic therapy and had a blood culture sample taken. We assumed that not all
- 140 suspected cases in need of blood culture would receive it (due to resource limitations or
- 141 insufficient blood-draw volume), meaning blood culture could only be completed for a portion of
- 142 the cohort, with results returned after 48 hours. Under the POCT intervention, all neonates with
- 143 suspected sepsis were tested using the POCT, and only those with a positive result immediately
- 144 initiated antibiotics.
- 145

146 We considered varying proportions of neonates without true bacterial sepsis eligible for

- 147 discharge after clinical evaluation and a negative result (blood culture or POCT) to represent
- 148 well presenting neonates. Discharge eligibility ranged (23%, 35%, 58%) based on the number of
- 149 neonates discharged within two, three, or five days from a neonatal intensive care unit (NICU)
- 150 (14). We assumed neonates with a false negative result remained hospitalized based on their

151 clinical presentation and received additional diagnostic testing. This created a delay to antibiotic 152 therapy, resulting in two additional days spent in the hospital and a 47% increase in the CFR 153 (15,16). Neonates without a true bacterial infection who received antibiotic therapy from empiric 154 treatment or false positive results and remained hospitalized were at risk of antibiotic-related 155 morbidities and HAIs. Neonates with a true bacterial infection (true positive) had an average 156 hospital stay of 16 days, while neonates without infection (false positive) had an average stay of 157 seven days (14). Neonates who contracted an HAI spent an additional 11 days in the hospital, for 158 a total stay of 18 days (17).

159

# 160 Cohort 2: Infants in primary health care facilities

161

162 At the community level, a modeled population of 5.000 infants (0–59 days of age) presented to 163 PHC facilities with pSBI (Table 1). Infants presenting with illness were either referred to a 164 higher-level care facility or received treatment on-site. The three categories of pSBI used by the 165 World Health Organization (WHO) were included in the model (from greatest to least severity): 166 critical illness, clinical severe infection (characterized by presence of at least one sign of severe infection), and fast breathing, defined as a respiratory rate >60 breaths/minute; modeled infants 167 168 were defined using these categories (11,18). Each category of pSBI had an assumed underlying 169 probability of true bacterial infection, which was varied in this analysis. Bacterial prevalence was 170 parameterized as lower in fast breathing infants and higher in critically ill infants, compared to 171 infants with clinical severe infection, reflecting how pSBI severity is correlated with true 172 bacterial infection (19).

173

174 Under the standard-of-care, per WHO guidelines, fast breathing infants 7–59 days of age were

treated on-site with oral amoxicillin, while infants with a clinical severe infection and critical

176 illness were referred to inpatient care with a pre-referral dose of antibiotics (10) (**Figure 1B**).

177 When referral was not feasible for infants with a clinical severe infection or critical illness, we

assumed they were treated on-site for up to seven days with WHO-recommended antibiotic

regimens. The probability of accepting referral to hospitalization (17%–90%) was varied to

180 reflect differently resourced contexts (11). CFRs for each category of pSBI were derived from

181 the literature (**Table 1**).

182

Using the POCT, all infants presenting with critical illness received a referral and a single dose of antibiotics regardless of their POCT result, while all fast-breathing infants were treated on-site without referral based on their POCT result. Infants presenting with a clinical severe infection were only referred for higher-level care, with one dose of antibiotics, if their POCT result was positive; otherwise, those with a negative POCT were monitored on-site. False positive infants with clinical severe infection received referral and treatment, while false negatives had an

- 189 assumed four-hour delay to antibiotic initiation, leading to an increased CFR (13,17).
- 190

191 Upon referral acceptance, infants entered the hospital model (**Figure 1A**) without additional

- 192 testing with the POCT. An assumed proportion underwent standard blood culture testing, leading
- 193 to discharge or continued antibiotic therapy. Hospitalized infants without a true underlying
- bacterial infection were at risk of HAIs, experiencing a higher CFR compared to community
- borne infections. These CFRs differed from those in the hospital model because different clinical
- 196 populations considered in each model (**Table 1**). Discharge eligibility among community
- 197 referred infants without bacterial infection was held constant at 58%.
- 198

# 199 Outcomes and Sensitivity Analysis

- 200
- 201 Modeled outcomes included the number of neonatal or infant deaths, days spent hospitalized,
- 202 number of HAIs, number of accepted hospital referrals, and antibiotic-associated morbidities.
- 203 Diagnostic impact was quantified as the percent reduction in deaths and hospital days, and the
- 204 number of HAIs and antibiotic-associated morbidities prevented through POCT use.
- 205

Diagnostic impact was assessed across a range of POCT sensitivities (80%–100%) and
specificities (70%–100%). Several sensitivity analyses were performed to understand the
performance of the POCT across various settings. In addition to discharge eligibility and referral
acceptance, true bacterial prevalence was varied among pSBI cases (6%, 12%, 24%) and the risk
of contracting an HAI (5%–20%) during the entire length of stay in both models. In the

- community level analysis, the CFR of HAIs was varied (12%, 29%).
- 212

# 213 Economic Analysis

- 214
- A threshold health economic analysis was performed to determine the total costs of care at baseline and with the POCT to determine at which price the POCT would be cost neutral to the healthcare system. Total costs of inpatient care in India and Uganda, representing different contexts, were gathered from the provider perspective and inflated to 2023 USD (21,22). The estimated cost of treatment and care for a single day in a tertiary hospital in India was \$118 for neonates with a true bacterial infection, and \$96 for those without (21). In Uganda, daily
- hospitalization costs for true bacterial infection was \$39 and \$31 for neonates without infection
- 222 (23). Healthy infants did not contribute any additional costs upon discharge. The maximum
- allowable cost for a POCT in a hospital setting was calculated by dividing hospitalization costs
- saved by the new diagnostic by the total number of POCTs administered to achieve cost savings.
- 225
- The maximum allowable cost of a POCT at PHCs was also determined using cost savings of
- community management and antibiotics. Data from the literature estimates that the cost of one
- course of oral amoxicillin at a PHC in India to cost \$1.29, and a single visit to a PHC facility to
- cost \$1.88 (21,24). From the provider perspective, an infant outpatient visit to a hospital after
- receiving a referral was estimated to be \$18.16 (24). Inpatient care costs at a hospital following

- referral were the same as described above for the hospital model. Healthcare costs in Uganda
- were used as a sensitivity analysis to represent other resource-limited settings, to identify how
- the costs of healthcare in different settings may reflect the maximum allowable cost for a POCT
- to remain cost neutral. In Uganda, community care and referral costs were reduced by 33% (23).
- 235 We also performed this economic analysis excluding infants with critical illness, as their POCT
- results did not change clinical practice in the model.

### **Table 1.** Model parameters for hospital and community settings. \**CFR: Case Fatality Rate*

Parameter	Value (%)						
Hospital Model							
Prevalence of culture-positive sepsis among suspected cases (19,25) - High - Moderate - Low	23.6 11.8 5.9						
Proportion of infections which are antimicrobial resistant (6)	49.96						
Proportion of suspected cases receiving blood culture (19)	59.51						
Blood culture sensitivity/specificity (26)	66.67/100						
Probability of antibiotic-related morbidities among antibiotic-treated children (26)	27.71						
Probability of acquiring hospital-associated infection during hospitalization among children without prior infection (27)	5, 10, 15, 20						
CFR*, no infection (6)	8.78						
CFR*, antibiotic susceptible infection (6)	29.00						
CFR*, antimicrobial resistant infection (6)	54.51						
CFR*, delayed antibiotic initiation (15)	68.16						
CFR*, antibiotic-associated mortality (28)	0.88						
Community Model							
Possible serious bacterial infection (11,12) <ul> <li>Proportion fast breathing (11)</li> <li>Proportion clinical severe infection (11)</li> <li>Proportion critical illness (11)</li> </ul>	38.72 53.94 7.34						
Bacterial prevalence (6,19,25) - Weighted average (0.5x, 1.0x, 2.0x) - Fast breathing (0.5x) - Clinical severe infection (1x) - Critical illness (2x)	5.2, 10.4, 20.8 3.0, 5.9, 11.8 5.9, 11.8, 23.6 11.8, 23.6, 47.2						
CFR* (community treated—pSBI) (11) - Fast breathing - Clinical severe infection - Critical illness	0.10 1.90 14.6						
CFR* (hospital-treated) (11,19,29) - Non-bacterial illness - True bacterial infection - Healthcare-associated infection	2.6 11.5 12.0, 29.0						
Referral acceptance (11,12)	17, 37, 69, 90						

239	Results
240	
241	Health outcomes of hospitalized neonates following POCT implementation
242	
243	In the hospital cohort, all neonates suspected of sepsis received empiric antibiotic therapy and
244	60% received blood culture. Blood culture results led to 5%-13% of neonates without a true
245	infection to be discharged early, depending on underlying discharge eligibility (23%-58%). The
246	final mortality rate among neonates who had or developed infection was 41.7%.
247	
248	When HAI risk was high (20% total risk), a POCT for neonatal sepsis in hospitals led to a net
249	reduction in neonatal deaths (0.3%-19.4% of deaths averted compared to baseline) at all test
250	sensitivities (80%-100%) and specificities (70%-100%) under the varying modeled proportions
251	of bacterial prevalence and discharge eligibility (Figure 2B). The percentage of neonatal deaths
252	prevented increased as POCT sensitivity increased, limiting false negatives and reducing delays
253	to antibiotic initiation for infected neonates.
254	
255	The percentage of neonatal deaths prevented with a POCT was greater with lower levels of
256	underlying bacterial prevalence (6%) and larger proportions of neonates eligible for discharge
257	(58%). In these contexts, test specificity was particularly important to rule out infection among
258	otherwise well-presenting neonates. Increasing test specificity led to greater percent reductions in
259	HAIs due to earlier discharge of neonates without infection and greater reductions in antibiotic-
260	associated morbidities due to fewer false positive results (Figure S1–S2). The impact of the
261	POCT increased when HAI risk was higher (20% overall risk vs. 5%), as HAIs constituted 9%-
262	33% of total infection related deaths when risk was low versus 28%–66% when risk was high
263	(Figure 2).
264	
265	Yet, in some contexts test sensitivity was the key driver of diagnostic impact. In settings with
266	low HAI risk (5%) and discharge eligibility (23%), but high bacterial prevalence (24%), excess
267	deaths occurred with the POCT compared to baseline $(0.2\%-1.6\%$ relative increase) when
268	sensitivity was below 85% due to increasing false negative results and subsequent delays in
269	antibiotic therapy among infected neonates. With a test sensitivity of 85%, specificity greater
270	than 80% was required to avoid increases in mortality across all contexts (Figure 2A).
271	
272	Earlier discharge leading to reduced HAI opportunity, resulted in a net reduction in hospital
273	days. The total number of hospital days was reduced by 8.2%–50.9% with POCT use (Figure
274	S3). The percent reduction in hospital days followed similar trends to neonatal deaths, with
275	respect to test specifications, discharge eligibility, and bacterial prevalence, but was not
276	significantly impacted by HAI risk.

# 277 Health outcomes of community-presenting infants following POCT implementation

278

In the modeled PHC cohort of 5,000 infants with pSBI, the proportion of infants correctly referred at baseline (i.e., infants with true bacterial infection) varied from 17% to 33% as the underlying bacterial prevalence increased (6%–24%). The proportion of correct referrals increased from 17% at baseline to 38% upon POCT implementation with the lowest modeled test specifications (80% sensitive, 70% specific) when bacterial prevalence was low and from 33% to 58% when bacterial prevalence was high (**Figure S4**). The relative impact of the POCT on appropriate referrals largely relied on high test specificity which led to more correct referrals.

- At baseline, 13–50 infant deaths occurred in PHC clinics and hospitals per 1,000 pSBI episodes across all modeled scenarios (**Figure S5**). Mortality increased as underlying bacterial prevalence and referral acceptance increased. Increasing referral acceptance led to increased hospital admission of infants without bacterial infection, posing risk of HAIs. HAI deaths constituted between 0.6%–44.7% of total deaths at baseline, depending on referral acceptance, bacterial
- prevalence, HAI acquisition rate, and associated CFRs within the hospital setting (Figure S6).
   293
- 294 A POCT to inform hospital referrals reduced total infant deaths, relative to baseline, when test 295 sensitivity and specificity were sufficiently high (Figure 3). At low levels of bacterial prevalence 296 and high levels of referral acceptance, and when HAI risk (20%) and mortality (29%) were high, 297 a POCT with high sensitivity and specificity could reduce infant deaths by up to 70% (Figure 298 **3B**). However, when sensitivity and specificity were low, there was an increase in deaths (3.5% -299 48% more deaths compared to baseline) at lower levels of referral acceptance and higher levels 300 of bacterial prevalence. This was attributed to delayed antibiotic initiation associated with a false 301 negative POCT result causing poorer clinical outcomes. The range of scenarios in which deaths 302 increased was greater when HAI risk and mortality were low (5% and 12% respectively) (Figure 303 **3A**).
- 304

To limit the number of deaths caused by false negative results, a high sensitivity of at least 90%
could be combined with a lower specificity (70%) to reduce total infant deaths across most
scenarios. However, under the worst-case scenarios, test sensitivity (≥98%) and specificity
(≥95%) would need to be exceedingly high to avoid excess infant mortality.

309

# 310 Sensitivity Analysis

311

312 Univariate sensitivity analyses of parameters used in both the hospital and community models,

- and their relationship with the number of infant deaths averted stratified by HAI risk are shown
- in Figure 4. Sensitivity and specificity were held at 85% and 80% in the hospital model, and
- 315 90% and 70% in the community model, representing the identified necessary minimum
- 316 specifications to reduce mortality across most scenarios.

### 317

318 At the hospital level, increasing test specificity, prompting more accurate negative diagnoses,

- drove the reduction in neonatal deaths by discharging earlier and reducing HAIs. HAI risk also
  substantially influenced the potential reductions in mortality; when HAI risk was low, there was
  less potential for the POCT to prevent deaths through reductions in unnecessary hospitalization.
- 322

At the community level, the probability of referral acceptance had an outsized influence on the potential impact of a POCT, dictating the potential for accurate negative diagnoses with a POCT to avert unnecessary hospitalization. Overall bacterial prevalence also shaped the impact of the POCT, with greater potential impact when prevalence was lower (i.e., when there were more healthy infants who benefitted from accurate non-referral).

328

### 329 Economic Analysis

330

331 POCT implementation among hospitalized neonates led to a reduction in hospitalization days 332 among the cohort (Figure S7), generating a 17%–43% reduction in total costs of treatment and 333 care at various levels of bacterial prevalence, proportion of neonates eligible for discharge, and 334 test sensitivity and specificity. Greater relative costs were saved when bacterial prevalence was 335 lower (6%) compared to when prevalence was higher (24%), indicating the benefits of the 336 diagnostic lie largely in identifying discharge-eligible neonates without infection (Figure S8, 337 S9). However, costs saved do not perfectly mirror trends in mortality shown in Figure 2 since 338 higher mortality is associated with fewer days spent in the hospital and thus lower healthcare 339 costs.

340

341 Cost savings were even more considerable with the implementation of a POCT at the community 342 level, saving 48%–81% of total costs of follow-up and treatment compared to baseline by 343 limiting inappropriate referrals and hospitalization days. Since fewer inappropriate referrals 344 occurred at baseline when bacterial prevalence was low, there were more cost savings with 345 POCT implementation. Across all bacterial prevalence and proportions of infants eligible for 346 discharge, cost savings increased with better test performance (higher sensitivity and/or 347 specificity) (Figure S10, S11). Excluding infants with critical illness from the threshold analysis

allowed the median cost of a POCT to increase, from \$0.86-\$1 in India and \$0.28-\$0.33 in
Uganda, across varied scenarios compared to allowable POCT costs including infants with

- 350 critical illness (Figure S12, S13).
- 351

352 To ensure that this test is financially feasible to implement across all settings and range of

353 uncertainty, our analysis indicates that a globally acceptable POCT for neonatal sepsis in a

- hospital setting should not exceed \$21 USD. Likewise, to ensure cost neutrality in the
- community setting, the lowest of the costs saved per test administered (\$3) should be selected as
- the optimal cost of the POCT at the PHC level (**Table S1, S2**). These results are reported

following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (Table
S3).

359

## 360 **Discussion**

361

362 Implementation of a sufficiently accurate POCT for sepsis detection in neonates or infants at 363 hospital and community level facilities can reduce overall morbidity and mortality, while 364 remaining cost neutral when priced appropriately. Although the exact impact of a POCT heavily 365 depends on the specific use case implementation context, our modeling found that a test with at 366 least 85% sensitivity and 80% specificity for hospitalized neonates and 90% sensitivity and 70% 367 specificity for community-presenting infants is likely to reduce mortality.

368

369 If test sensitivity were to be lower than these values, deaths caused by missed diagnosis of true

370 sepsis cases and ensued delays in antibiotic initiation could lead to overall increases in mortality.

371 However, there were instances where tests of low sensitivity and high specificity, due to large

reductions in unnecessary hospitalization, antibiotic use, and HAI acquisition among uninfected

373 patients, could lead to declines in mortality and costs despite the increased number of false

negative diagnoses. While the overall benefits of a POCT may outweigh the consequences of
 false negatives in these scenarios, a test sensitivity well above 80% should remain the diagnostic

false negatives in these scenarios, a test sensitivity well above 80% should remain the diagnosticcriterion, with a sensitivity of 90% serving as an ideal standard. A POCT with a low sensitivity

would have limited utility in independently ruling out sepsis among neonates and infants.

378

379 Along with sensitivity, test specificity needs to be sufficiently high to reduce unnecessary 380 hospitalizations and HAIs. However, even a test with lower specificity will improve upon the 381 standard of care and can be tolerated in some contexts. In the hospital setting, a specificity of 382 80% combined with a sensitivity of 85% saw a net reduction in neonatal deaths. However, in the 383 community setting, 70% specificity with 90% sensitivity led to reduced infant deaths in most 384 scenarios, excluding contexts with low referral acceptance (17%) and high bacterial prevalence 385 (24%). Under these circumstances, even 100% specificity would be insufficient unless sensitivity 386 was 98%, principally speaking to the importance of evaluating contextual factors when 387 implementing a POCT.

388

389 Given the complexity in diagnosing sepsis in neonates and infants, it is likely that a POCT be 390 used as part of a diagnostic package, which may affect overall diagnostic impact and modify the 391 requirements and trade-offs between POCT sensitivity and specificity. Although a true POCT may be difficult to develop, a near POCT may have reduced impact compared to our modeled 392 393 results by creating delays to test results. The POCT could be one component of a clinical 394 algorithm that includes signs, symptoms and risk factors, thereby reducing the required POCT 395 performance to achieve net benefits through the diagnostic algorithm. Additionally, we did not 396 consider the effect of positive POCT results on the timeliness to appropriate antibiotic initiation

and consequent potential improved health outcomes, compared to empiric therapy alone.

- **398** Therefore, the POCT could have benefits not captured in this analysis.
- 399

400 A key limitation of this analysis is that model parameters, assumptions, and costs were all 401 derived from tertiary hospital and PHC studies in India and Uganda, and thus may not perfectly 402 represent other resource-limited settings. For example, blood culture was assumed to be 100% 403 specific in diagnosing true negatives, but culture contamination is common in these settings, 404 thereby creating more false positive results, potentially altering health outcomes. Likewise, the 405 possibility of false negative results due to inadequate blood volume for optimal culture 406 performance is also a possibility that could impact our estimates. Additionally, the model 407 contains assumptions that may differ across the diverse environments where sepsis in neonates 408 and infants is common, including bacterial prevalence, resistance profiles, length of hospital stay, 409 and rates of HAIs. To account for this variability, several parameters were varied to improve 410 model sensitivity. While we expect relative differences between the POCT and baseline 411 standard-of-care to be consistent, these results should be interpreted with discretion as these 412 parameters continue to evolve with potential stock-outs of appropriate antibiotic treatment and

- 413 exponential growth of AMR in resource-limited settings.
- 414

415 Additionally, several simplifying assumptions regarding clinical management and outcomes

416 were made, which may not capture all the challenges of clinical pathways in diagnosing sepsis.

417 For example, infants may become lost to follow-up after PHC referral, incurring unknown health

- 418 outcomes and costs. Patients were functionally dichotomized into those who were being
- 419 appropriately treated with antibiotics and untreated; in reality, treatment of bacterial sepsis is
- 420 complex, and there are clinical benefits to continued refinement of antibiotic regimens that could
- 421 not be incorporated here. Similarly, there are other indirect and long-term benefits to
- 422 implementing POCTs that are not explicitly included in this model, including reductions in the
- 423 spread of AMR and preservation of first-line antibiotics in low-resource settings. Finally, we
- 424 assumed the POCT performed as intended with respect to sensitivity and specificity, but ignored
- the possibility of invalid results, which may come with a new technology. Clarifying diagnostic
- 426 algorithms based on available and developing technologies, and the clinical management that
- 427 accompany them are a necessity for accurately costing these tools in the future.
- 428

429 This modeling analysis serves as a tool for understanding the necessary technical specifications,

- 430 which should be taken into consideration with other technical parameters (i.e., blood volume,
- 431 sample preparation guidelines, and time to result) that can be used to guide the development of a
- 432 POCT as an aid to diagnose sepsis in hospitalized neonates and community-presenting infants.
- 433 An accurate POCT could improve time to diagnosis and generate net reductions in hospital days,
- 434 HAIs, and deaths, while promoting the de-escalation of antimicrobials in resource-limited
- 435 settings. Our results displayed a critical trade-off between HAI-related deaths prevented and
- those caused by a false-negative diagnosis, suggesting that a high sensitivity should be

- 437 prioritized over specificity to avoid potential delays in antibiotic initiation. Given the nature of
- the settings in which the POCT will be used, its cost should not exceed \$21 in a hospital setting
- 439 and \$3 in a community setting.
- 440
- 441 Future research should focus on bridging the current gaps in data availability regarding the
- 442 occurrence and clinical management of sepsis in hospitals and community settings to generate
- 443 more robust and context-specific estimates of the impact of a POCT, and its downstream effect
- 444 on AMR. Urgent investments in diagnostics development are needed to accelerate access to
- 445 diagnostic solutions for the vulnerable populations most impacted by neonatal sepsis.

### 446 Author Contributions

447 Conceptualization: BG, CF, BEN. Data curation: JMC, MAH. Methodology: JMC, MAH, KHG,

- 448 SK, BEN. Formal analysis: JMC, MAH, KHG. Investigation: JMC, MAH, BG, BB VC, KHG.
- 449 Supervision: BG, CF, BB, SK, BEN, KHG. Writing original draft: JMC, MAH. Writing –
- 450 review and editing: JMC, MAH, KHG, BG, BB, VC, SK, NS, GC, FF, CF, BEN.
- 451

### 452 Acknowledgements

- 453 Not applicable.
- 454

### 455 **Competing Interests**

456 FF is a trustee of Neotree, a UK registered charity that provides technology, software

- 457 information, education and support to newborn healthcare workers and medical practitioners in
- 458 low resource settings (charity number: 1186748). All other authors declare no conflict of interest.
- 459 The funders had no role in the design of the study, the collection, analyses, or interpretation of
- 460 data, the writing of the manuscript, or the decision to publish the results.
- 461

## 462 Ethical Approval

- 463 This research utilizes publicly available data from the literature; therefore, formal ethical
- 464 approval was not required. However, ethical considerations were included throughout the
- 465 research process as transparency was maintained in the reporting of our modeling methodology.
- 466 This statement affirms our commitment to ethical conduct in research, even in the absence of
- 467 formal approval.
- 468

### 469 Data Availability Statement

- 470 We acknowledge the importance of transparent and responsible data sharing to foster scientific
- 471 collaboration and advance research. All data used for this study are presented in the manuscript
- 472 and gathered from publicly available literature, and therefore do not necessitate any information
- 473 de-identification. For additional information, interested parties can contact JMC
- 474 (j.m.chevalier@amsterdamumc.nl) or MAH (m.hansen@amsterdamumc.nl).
- 475

## 476 Funding

- 477 This work was supported via FIND by the UK Department of Health and Social Care as part of
- the Global AMR Innovation Fund (GAMRIF) and with support from the Ministry of Foreign
- 479 Affairs of the Government of the Netherlands. GAMRIF is a One Health UK aid fund that
- 480 supports research and development around the world to reduce the threat of antimicrobial
- 481 resistance in humans, animals and the environment for the benefit of people in low- and middle-
- 482 income countries (LMICs). The views expressed in this publication are those of the authors and
- 483 not necessarily those of the UK Department of Health and Social Care. FF is supported by a
- 484 Wellcome Trust Early Career Award (227076/Z/23/Z).


### 485 **References**

- 486 1. CME Info Child Mortality Estimates [Internet]. [cited 2024 Oct 7]. Available from:
   487 https://childmortality.org/causes-of-death/data
- 488 2. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global
  489 incidence and mortality of neonatal sepsis: A systematic review and meta-analysis. Vol. 106,
  490 Archives of Disease in Childhood. BMJ Publishing Group; 2021. p. 745–52.
- 491 3. Adatara P, Afaya A, Salia SM, Afaya RA, Konlan KD, Agyabeng-Fandoh E, et al. Risk
  492 Factors Associated with Neonatal Sepsis: A Case Study at a Specialist Hospital in Ghana. Sci
  493 World J. 2019;2019.
- 494 4. Kirby R, Palamountain K, Spotswood N, Goldfarb D. Use Cases Sepsis Diagnostic Infection
  495 Prevention and Control [Internet]. Available from:
- 496 https://www.unicef.org/supply/media/2946/file/sepsis-diagnostic-use-cases.pdf
- 497 5. Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, et al. Best Practices of
- Blood Cultures in Low- and Middle-Income Countries. Vol. 6, Frontiers in Medicine.
  Frontiers Media S.A.; 2019.
- 6. Agarwal R, Chaurasia S, Sankar MJ, Yadav CP, Arya S, Kapil A, et al. Characterisation and
  antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi,
  India: a cohort study. Lancet Glob Health. 2016 Oct;4(10):e752–60.
- 503 7. Celik IH, Hanna M, Canpolat FE, Pammi M. Diagnosis of neonatal sepsis: the past, present
  504 and future. Vol. 91, Pediatric Research. Springer Nature; 2022. p. 337–50.
- 8. Gude SS, Peddi NC, Vuppalapati S, Gopal SV, Ramesh HM, Gude SS. Biomarkers of
  Neonatal Sepsis: From Being Mere Numbers to Becoming Guiding Diagnostics. Cureus. 2022
  Mar;
- 9. Rani U, Lewis LE, Chawla K, Naha A. Preventable contributors to the neonatal healthcareassociated infections: a uni-center analytical study from South India. F1000Research. 2022
  Apr 25;11:454.
- 511 10. Organization WH. Operationalizing management of sick young infants with possible
  512 serious bacterial infection (PSBI) when referral is not feasible in the context of existing
  513 maternal, newborn, and child health programmes [Internet]. 2015. Available from:
- 514 https://apps.who.int/iris/bitstream/handle/10665/259592/9789241512930-eng.pdf?sequence=1
- 515 11. Nisar YB, Aboubaker S, Arifeen SE, Ariff S, Arora N, Awasthi S, et al. A multi-country
  516 implementation research initiative to jump-start scale-up of outpatient management of
  517 possible serious bacterial infections (PSBI) when a referral is not feasible: Summary findings
  518 and implications for programs. PLoS ONE. 2022 Jun;17(6 June).
- 519 12. Roy S, Patil R, Apte A, Thibe K, Dhongade A, Pawar B, et al. Feasibility of
  520 implementation of simplified management of young infants with possible serious bacterial

- infection when referral is not feasible in tribal areas of Pune district, Maharashtra, India. PLoS
  ONE. 2020 Aug;15(8 August).
- 523 13. Gleeson B, Ferreyra C, Palamountain K, Jacob ST, Spotswood N, Kissoon N, et al. A call
  524 to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle525 income countries. BMJ Glob Health. 2024 Sep 1;9(9):e015862.
- 526 14. P K, S KK, K V. A study on the length of stay of neonates in neonatal intensive care unit
  527 in a referral hospital in India. Int J Contemp Pediatr. 6(2):746–9.
- 528 15. Schmatz M, Srinivasan L, Grundmeier RW, Elci OU, Weiss SL, Masino AJ, et al.
  529 Surviving Sepsis in a Referral Neonatal Intensive Care Unit: Association between Time to
  530 Antibiotic Administration and In-Hospital Outcomes. J Pediatr. 2020 Feb;217:59-65.e1.
- 531 16. Sisay EA, Mengistu BL, Taye WA, Fentie AM, Yabeyu AB. Length of Hospital Stay and
  532 Its Predictors Among Neonatal Sepsis Patients: A Retrospective Follow-Up Study. Int J Gen
  533 Med. 2022;15:8133–42.
- Murki S, Vardhelli V, Deshabhotla S, Sharma D, Pawale D, Kulkarni D, et al. Predictors
  of length of hospital stay among preterm infants admitted to neonatal intensive care unit: Data
  from a multicentre collaborative network from India (INNC: Indian National Neonatal
  Collaborative). J Paediatr Child Health. 2020 Oct;56(10):1584–9.
- Mukhopadhyay R, Arora NK, Sharma PK, Dalpath S, Limbu P, Kataria G, et al. Lessons
  from implementation research on community management of possible serious bacterial
  infection (pSBI) in young infants (0-59 days), when the referral is not feasible in Palwal
  District of Haryana, India. PLoS ONE. 2021 Jul;16(7 July).
- 542 19. Saha SK, Schrag SJ, Arifeen SE, Mullany LC, Islam MS, Shang N, et al. Causes and
  543 incidence of community-acquired serious infections among young children in south Asia
  544 (ANISA): an observational cohort study. The Lancet. 2018 Jul;392(10142):145–59.
- 545 20. Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, et al. Delayed
  546 Antimicrobial Therapy Increases Mortality and Organ Dysfunction Duration in Pediatric
  547 Sepsis. Crit Care Med. 2014;42(11):2409–17.
- 548 21. Karambelkar G, Malwade S, Karambelkar R. Cost analysis of Healthcare in a Private
  549 sector Neonatal Intensive Care Unit in India. Indian Pediatr. 2016 Sep 8;53(9):793–5.
- Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and
   Currency Changes Within Health Economic Studies. Value Health. 2019 Sep;22(9):1026–32.
- 552 23. Nichols BE, Sigaloff KCE, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, et al.
  553 Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of 554 drug-resistant HIV: A mathematical modelling study. J Int AIDS Soc. 2014;17(1).

- 555 24. Chauhan AS, Prinja S, Selvaraj S, Gupta A, Muraleedharan VR, Sundararaman T. Cost
  556 of delivering primary healthcare services through public sector in India. Indian J Med Res.
  557 2022 Sep;156(3):372–80.
- 558 25. Milton R, Gillespie D, Dyer C, Taiyari K, Carvalho MJ, Thomson K, et al. Neonatal
  559 sepsis and mortality in low-income and middle-income countries from a facility-based birth
  560 cohort: an international multisite prospective observational study. Lancet Glob Health. 2022
  561 May;10(5):e661–72.
- 562 26. Ahmad A, Iram S, Hussain S, Yusuf NW. Diagnosis of paediatric sepsis by automated
  563 blood culture system and conventional blood culture. JPMA J Pak Med Assoc. 2017
  564 Feb;67(2):192–5.
- Mathur P, Malpiedi P, Walia K, Srikantiah P, Gupta S, Lohiya A, et al. Health-careassociated bloodstream and urinary tract infections in a network of hospitals in India: a
  multicentre, hospital-based, prospective surveillance study. Lancet Glob Health. 2022
  Sep;10(9):e1317–25.
- 569 28. Ting JY, Synnes A, Roberts A, Deshpandey A, Dow K, Yoon EW, et al. Association
  570 between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants
  571 without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr. 2016
  572 Dec;170(12):1181–7.
- Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospitalacquired neonatal infections in developing countries. The Lancet. 2005 Mar;365(9465):1175–
  88.

- 577 Figure 1. Conceptual diagram for clinical cascade for a point-of-care test for neonatal sepsis at the primary health
- 578 care level and hospital. \*POCT: point-of-care test, PHC: primary health care, FB: fast-breathing, CSI: clinical
- 579 severe infection, CI: critical illness, HAI: hospital-associated infection



582 Figure 2. Percent reduction in neonatal deaths in a hospital setting, across modeled bacterial prevalence and 583 proportion of neonates eligible for discharge, by test specificity and sensitivity, when A) the risk of hospital-

584 associated infections is low (5%) or **B**) high (20%).

585

A)		Percent Eligible for Discharge														
				23	1%					58	3%					
	100% -	6.5%	6.9%	7.4%	7.8%	8.1%	8.3%	9.1%	9.6%	10.0%	10.5%	10.7%	10.9%			
	98% -	6.3%	6.8%	7.2%	7.7%	7.9%	8.1%	8.9%	9.4%	9.8%	10.2%	10.5%	10.7%			
	95% -	6.1%	6.5%	7.0%	7.4%	7.7%	7.8%	8.6%	9.0%	9.5%	9.9%	10.2%	10.3%			
	90% -	5.7%	6.1%	6.5%	7.0%	7.3%	7.4%	8.0%	8.5%	8.9%	9.4%	9.6%	9.8%	6%		
	85% -	5.3%	5.7%	6.1%	6.6%	6.8%	7.0%	7.5%	7.9%	8.4%	8.8%	9.1%	9.2%	%		
	80% -	4.8%	5.3%	5.7%	6.2%	6.4%	6.6%	6.9%	7.4%	7.8%	8.3%	8.5%	8.7%			
city	75% -	4.4%	4.9%	5.3%	5.7%	6.0%	6.2%	6.4%	6.8%	7.3%	7.7%	8.0%	8.1%			
lest specificity	70% -	4.0%	4.4%	4.9%	5.3%	5.6%	5.8%	5.8%	6.3%	6.7%	7.2%	7.4%	7.6%			
	100% -	-0.2%	1.0%	2.2%	3.4%	4.2%	4.7%	1.3%	2.5%	3.7%	4.9%	5.6%	6.1%			
e	98% -	-0.3%	0.9%	2.1%	3.3%	4.1%	4.6%	1.1%	2.3%	3.6%	4.8%	5.5%	6.0%			
	95% -	-0.5%	0.8%	2.0%	3.2%	3.9%	4.4%	0.9%	2.2%	3.4%	4.6%	5.3%	5.8%			
	90% -	-0.7%	0.5%	1.7%	3.0%	3.7%	4.2%	0.6%	1.9%	3.1%	4.3%	5.0%	5.5%	24%		
	85% -	-0.9%	0.3%	1.5%	2.7%	3.5%	3.9%	0.3%	1.5%	2.8%	4.0%	4.7%	5.2%	%		
	80% -	-1.2%	0.1%	1.3%	2.5%	3.2%	3.7%	0.0%	1.2%	2.5%	3.7%	4.4%	4.9%			
	75% -	-1.4%	-0.2%	1.0%	2.3%	3.0%	3.5%	-0.3%	0.9%	2.1%	3.4%	4.1%	4.6%		Percent Deaths Av	
	70% -	-1.6%	-0.4%	0.8%	2.0%	2.8%	3.2%	-0.6%	0.6%	1.8%	3.1%	3.8%	4.3%			
	L	80%	85%	90%	95%	98%	100%	80%	85%	90%	95%	98%	100%		15 10	
B)	[			23	3%				58%							
	100% -	9.4%	9.7%	10.1%	10.5%	10.7%	10.8%	18.0%	18.4%	18.7%	19.1%	19.3%	19.4%		5% 0% -5%	
	98% -	9.2%	9.5%	9.9%	10.2%	10.4%	10.6%	17.6%	18.0%	18.3%	18.7%	18.9%	19.0%			
	95% -	8.8%	9.2%	9.5%	9.9%	10.1%	10.3%	17.0%	17.4%	17.7%	18.1%	18.3%	18.5%			
	90% -	8.3%	8.6%	9.0%	9.3%	9.6%	9.7%	16.0%	16.4%	16.7%	17.1%	17.3%	17.5%	6%		
	85% -	7.7%	8.1%	8.4%	8.8%	9.0%	9.1%	15.0%	15.4%	15.8%	16.1%	16.3%	16.5%	%		
	80% -	7.2%	7.5%	7.9%	8.2%	8.4%	8.6%	14.1%	14.4%	14.8%	15.1%	15.3%	15.5%			
city	75% -	6.6%	7.0%	7.3%	7.7%	7.9%	8.0%	13.1%	13.4%	13.8%	14.1%	14.4%	14.5%			
ecilio	70% -	6.0%	6.4%	6.8%	7.1%	7.3%	7.5%	12.1%	12.4%	12.8%	13.2%	13.4%	13.5%			
l est specificity	100% -	2.3%	3.4%	4.5%	5.5%	6.2%	6.6%	7.6%	8.6%	9.7%	10.8%	11.5%	11.9%			
ě	98% -	2.2%	3.3%	4.3%	5.4%	6.1%	6.5%	7.3%	8.4%	9.5%	10.6%	11.2%	11.7%			
	95% -	2.0%	3.0%	4.1%	5.2%	5.9%	6.3%	7.0%	8.0%	9.1%	10.2%	10.9%	11.3%			
	90% -	1.6%	2.7%	3.8%	4.9%	5.5%	5.9%	6.3%	7.4%	8.5%	9.6%	10.3%	10.7%	24%		
	85% -	1.3%	2.4%	3.4%	4.5%	5.2%	5.6%	5.7%	6.8%	7.9%	9.0%	9.6%	10.1%	%		
	80% -	0.9%	2.0%	3.1%	4.2%	4.8%	5.3%	5.1%	6.2%	7.3%	8.4%	9.0%	9.5%			
	75% -	0.6%	1.7%	2.8%	3.8%	4.5%	4.9%	4.5%	5.6%	6.7%	7.8%	8.4%	8.9%			
	70% -	0.3%	1.3%	2.4%	3.5%	4.1%	4.6%	3.9%	5.0%	6.1%	7.2%	7.8%	8.3%			
	L	80%	85%	90%	95%	98%	100%	80%	85%	90%	95%	98%	100%	_		

**Bacterial Prevalence** erted

587 Figure 3. Percent of deaths averted compared to baseline when using the point-of-care test at the community level,
588 by test sensitivity, specificity, bacterial prevalence, and referral acceptance, when A) HAI risk and mortality are low

589 (5%, 12%), and B) HAI risk and mortality are high (20%, 29%)

590

Α

**Referral Acceptance** 

~							noniai /		scopiai									
				17	'%						69							
	100% -	12.4%	15.3%	18.1%	20.9%	22.6%	23.8%		58.5%	59.1%	59.7%	60.4%	60.7%	61.0%				
	98% -	12.0%	14.8%	17.6%	20.5%	22.2%	23.3%		57.2%	57.9%	58.5%	59.1%	59.5%	59.8%				
	95% -	11.2%	14.1%	16.9%	19.8%	21.5%	22.6%		55.4%	56.0%	56.7%	57.3%	57.7%	57.9%				
	90% -	10.1%	12.9%	15.7%	18.6%	20.3%	0.3% 21.4%		52.4%	53.0%	53.6%	54.3%	54.6%	54.9%	6			
	85% -	8.9%	11.7%	14.5%	17.4%	19.1%	20.2%		49.3%	49.9%	50.6%	51.2%	51.6%	51.8%	%			
	80% -	7.7%	10.5%	13.4%	16.2%	17.9%	19.0%		46.3%	46.9%	47.5%	48.2%	48.5%	48.8%				
Z	75% -	6.5%	9.3%	12.2%	15.0%	16.7%	17.8%		43.2%	43.8%	44.5%	45.1%	45.5%	45.7%				
Specificity	70% -	5.3%	8.1%	11.0%	13.8%	15.5%	16.6%		40.2%	40.8%	41.4%	42.1%	42.4%	42.7%				
pec	100% -	-51.9%	-37.4%	-22.9%	-8.3%	0.4%	6.2%		4.1%	10.0%	15.9%	21.8%	25.4%	27.8%				
S	98% -	-52.0%	-37.5%	-23.0%	-8.5%	0.2%	6.0%		3.6%	9.5%	15.4%	21.3%	24.8%	27.2%				
	95% -	-52.2%	-37.7%	-23.2%	-8.7%	0.1%	5.9%		2.7%	8.7%	14.6%	20.5%	24.0%	26.4%				
	90%-	-52.5%	-38.0%	-23.5%	-9.0%	-0.3%	5.6%		1.4%	7.3%	13.2%	19.1%	22.6%	25.0%	24			
	85% -	-52.8%	-38.3%	-23.8%	-9.3%	-0.6%	5.2%		0.0%	5.9%	11.8%	17.7%	21.2%	23.6%	%			
	80% -	-53.1%	-38.6%	-24.1%	-9.6%	-0.9%	4.9%		-1.4%	4.5%	10.4%	16.3%	19.8%	22.2%				
	75%-	-53.4%	-38.9%	-24.4%	-9.9%	-1.2%	4.6%		-2.8%	3.1%	9.0%	14.9%	18.5%	20.8%		Percent Deaths	Racterial Prevalence	
	70% -	-53.7%	-39.2%	-24.7%	-10.2%	-1.5%	4.3%		-4.2%	1.7%	7.6%	13.5%	17.1%	19.4%		Averted G		
		80%	85%	90%	95%	98%	100%		80%	85%	90%	95%	98%	100%		50%		
в	[			17	%						69			25% reva				
	100% -	25.3%	27.7%	30.0%	32.4%	33.8%	34.7%		68.8%	69.2%	69.6%	70.0%	70.3%	70.5%		-25% Ben		
	98% -	24.6%	27.0%	29.3%	31.7%	33.1%	34.0%		67.4%	67.8%	68.2%	68.6%	68.9%	69.0%		-50% &		
	95% -	23.6%	25.9%	28.3%	30.6%	32.0%	33.0%		65.3%	65.7%	66.1%	66.5%	66.8%	66.9%				
	90% -	21.8%	24.2%	26.5%	28.9%	30.3%	31.3%		61.7%	62.2%	62.6%	63.0%	63.2%	63.4%	6			
	85% -	20.1%	22.4%	24.8%	27.2%	28.6%	29.5%		58.2%	58.6%	59.1%	59.5%	59.7%	59.9%	%			
	80% -	18.4%	20.7%	23.1%	25.4%	26.8%	27.8%		54.7%	55.1%	55.5%	55.9%	56.2%	56.4%				
>	75% -	16.6%	19.0%	21.3%	23.7%	25.1%	26.0%		51.2%	51.6%	52.0%	52.4%	52.7%	52.8%				
ficity	70% -	14.9%	17.2%	19.6%	22.0%	23.4%	24.3%		47.7%	48.1%	48.5%	48.9%	49.2%	49.3%				
Specificit	100%	-44.9%	-31.1%	-17.3%	-3.5%	4.8%	10.3%	1	20.4%	25.2%	30.0%	34.8%	37.7%	39.6%				
S	98%-	-45.1%	-31.3%	-17.5%	-3.7%	4.6%	10.1%		19.6%	24.4%	29.2%	34.0%	36.9%	38.8%				
	95% -	-45.4%	-31.6%	-17.8%	-4.0%	4.3%	9.8%			23.3%								
	90% -	-46.0%	-32.1%	-18.3%	-4.5%	3.8%	9.3%		16.5%	21.3%	26.1%	30.9%	33.8%	35.7%	N			
	85% -	-46.5%	-32.7%	-18.8%	-5.0%	3.2%	8.8%		14.5%	19.3%	24.1%	28.9%	31.8%	33.7%	4%			
	80% -	-47.0%	-33.2%	-19.4%	-5.6%	2.7%	8.3%		12.5%	17.3%	22.1%	26.9%	29.8%	31.7%				
	75%-	-47.5%	-33.7%	-19.9%	-6.1%	2.2%	7.7%		10.5%	15.3%	20.1%	24.9%	27.8%	29.7%				
	70%-	-48.0%	-34.2%	-20.4%	-6.6%	1.7%	7.2%		8.5%	13.3%	18.1%	22.9%	25.8%	27.7%				
		80%	85%	90%	95%	98%	100%	- 1	80%	85%	90%	95%	98%	100%				
Sensitivity																		

Figure 4. Univariate sensitivity analysis of A) hospital model parameters or B) community model parameters and
the correlated number of neonatal deaths averted, stratified by A) hospital-associated infection risk or B) hospitalassociated infection risk and case fatality rate. The absolute number of deaths averted is shown on the X-axis, while
the corresponding percentage is shown on the error bar label. The vertical red, dashed line represents the number of
deaths averted when all other variables are held at their constant A) specificity: 80%, sensitivity: 85%, discharge

eligibility: 35%, bacterial prevalence: 12% or B) specificity: 70%, sensitivity: 90%, referral acceptance: 37%,

598 bacterial prevalence: 12%. \*HAI: hospital-associated infection, CFR: case fatality rate

599

